Immuno-genomic profiling of patients with inflammatory bowel disease: A systematic review of genetic and functional in vivo studies of implicated genes

Inflammatory Bowel Diseases

Volumn 20, Issue 10, 2014, Pages 1813-1819

  Coelho, Tracy ^a   Andreoletti, Gaia ^a   Ashton, James J ^a   Pengelly, Reuben J ^a   Gao, Yifang ^b   Ramakrishnan, Ananth ^b   Batra, Akshay ^a   Beattie, Robert M ^a   Williams, Anthony P ^b   Ennis, Sarah ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Crohn's disease; Functional studies; Genetic studies; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 10 RECEPTOR BETA; BIOLOGICAL MARKER;

AUTOPHAGY; COMPUTER MODEL; CROHN DISEASE; DENDRITIC CELL; EMBASE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HOMOZYGOTE; HUMAN; IL 10 GENE; IMMUNOPATHOGENESIS; IN VIVO STUDY; MACROPHAGE; MEDICAL LITERATURE; MEDLINE; NEXT GENERATION SEQUENCING; NOD2 GENE; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE TRAIT LOCUS; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); PROCEDURES; PROGNOSIS;

BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLAMMATORY BOWEL DISEASES; META-ANALYSIS AS TOPIC; PROGNOSIS;

EID: 84925788297     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000174     Document Type: Review

References (57)

1. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
2. Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut. 2011;60:1739-1753.
3. Hansen R, Berry SH, Mukhopadhya I, et al. The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: the BISCUIT study. PLoS One. 2013;8:e58825.
4. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
5. Crohn BB, Ginzburg L, Oppenheimer GD. Landmark article Oct. 15, 1932. Regional ileitis. A pathological and clinical entity. By Burril B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer. JAMA. 1984;251:73-79.
6. Peeters M, et al. Familial aggregation in Crohn's disease: increased ageadjusted risk and concordance in clinical characteristics. Gastroenterology. 1996;111:597-603.
7. Henderson P, Satsangi J. Genes in inflammatory bowel disease: lessons from complex diseases. Clin Med. 2011;11:8-10.
8. Tysk C, Lindberg E, Järnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut. 1988;29:990-996.
9. Cardinale CJ, Kelsen JR, Baldassano RN, et al. Impact of exome sequencing in inflammatory bowel disease. World J Gastroenterol. 2013;19:6721-6729.
10. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
11. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
12. Van Limbergen J, Radford-Smith G, Satsangi J. Advances in IBD genetics. Nat Rev Gastroenterol Hepatol. 2014;11:372-385.
13. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43:1066-1073.
14. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62:1653-1664.
15. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol. 2008;14:401-407.
16. Johansson ME, Gustafsson JK, Holmén-Larsson J, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2014;63:281-291.
17. Fritz T, Niederreiter L, Adolph T, et al. Crohn's disease: NOD2, autophagy and ER stress converge. Gut. 2011;60:1580-1588.
18. Muzes G, Tulassay Z, Sipos F. Interplay of autophagy and innate immunity in Crohn's disease: a key immunobiologic feature. World J Gastroenterol. 2013;19:4447-4454.
19. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
20. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629-1636.
21. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
22. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033-2045.
23. Chaudhry A, Samstein RM, Treuting P, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34:566-578.
24. Engelhardt KR, Shah N, Faizura-Yeop I, et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;131:825-830.
25. Moran CJ, Walters TD, Guo CH, et al. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 2013;19:115-123.
26. Coskun M, Salem M, Pedersen J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1-8.
27. Graham DB, Xavier RJ. From genetics of inflammatory bowel disease towards mechanistic insights. Trends Immunol. 2013;34:371-378.
28. Li J, Moran T, Swanson E, et al. Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet. 2004;13:1715-1725.
29. Van Heel DA, Ghosh S, Butler M, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet. 2005;365:1794-1796.
30. Van Heel DA, Hunt KA, Ghosh S, et al. Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. Eur J Immunol. 2006;36:1629-1635.
31. Van Heel DA, Hunt KA, King K, et al. Detection of muramyl dipeptidesensing pathway defects in patients with Crohn's disease. Inflamm Bowel Dis. 2006;12:598-605.
32. Peeters H, Bogaert S, Laukens D, et al. CARD15 variants determine a disturbed early response of monocytes to adherent-invasive Escherichia coli strain LF82 in Crohn's disease. Int J Immunogenet. 2007;34:181-191.
33. Hedl M, Li J, Cho JH, et al. Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci U S A. 2007;104:19440-19445.
34. Lappalainen M, Paavola-Sakki P, Halme L, et al. Novel CARD15/NOD2 mutations in Finnish patients with Crohn's disease and their relation to phenotypic variation in vitro and in vivo. Inflamm Bowel Dis. 2008;14:176-185.
35. Seidelin JB, Broom OJ, Olsen J, et al. Evidence for impaired CARD15 signalling in Crohn's disease without disease linked variants. PLoS One. 2009;4:e7794.
36. Kuuliala K, Lappalainen M, Turunen U, et al. Detection of muramyl dipeptide-sensing pathway defects in monocytes of patients with Crohn's disease using phospho-specific whole blood flow cytometry. Scand J Clin Lab Invest. 2013;73:494-502.
37. Rahman MK, Midtling EH, Svingen PA, et al. The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival. J Immunol. 2010;184:7247-7256.
38. Van Heel DA, Ghosh S, Hunt KA, et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut. 2005;54:1553-1557.
39. Braat H, Stokkers P, Hommes T, et al. Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn's disease patients. J Mol Med (Berl). 2005;83:601-609.
40. Canto E, Moga E, Ricart E, et al. MDP-Induced selective tolerance to TLR4 ligands: impairment in NOD2 mutant Crohn's disease patients. Inflamm Bowel Dis. 2009;15:1686-1696.
41. Brosbol-Ravnborg A, Hvas CL, Agnholt J, et al. Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways. Clin Exp Immunol. 2009;155:487-495.
42. Butler M, Chaudhary R, Van Heel DA, et al. NOD2 activity modulates the phenotype of LPS-stimulated dendritic cells to promote the development of T-helper type 2-like lymphocytes-possible implications for NOD2-associated Crohn's disease. J Crohns Colitis. 2007;1:106-115.
43. Vissers M, Remijn T, Oosting M, et al. Respiratory syncytial virus infection augments NOD2 signaling in an IFN-beta-dependent manner in human primary cells. Eur J Immunol. 2012;42:2727-2735.
44. Kullberg BJ, Ferwerda G, De Jong DJ, et al. Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology. 2008;123:600-605.
45. Netea MG, Ferwerda G, De Jong DJ, et al. The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2-but also Nod1-activating peptidoglycan agonists. J Biol Chem. 2005;280:35859-35867.
46. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010;16:90-97.
47. Koss K, Satsangi J, Fanning GC, et al. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun. 2000;1:185-190.
48. Van Der Linde K, Boor PP, Sandkuijl LA, et al. A Gly15Arg mutation in the interleukin-10 gene reduces secretion of interleukin-10 in Crohn disease. Scand J Gastroenterol. 2003;38:611-617.
49. Begue B, Verdier J, Rieux-Laucat F, et al. Defective IL-10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 2011;106:1544-1555.
50. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143:347-355.
51. Mao H, Yang W, Lee PP, et al. Exome sequencing identifies novel compound heterozygous mutations of IL-10 receptor 1 in neonatal-onset Crohn's disease. Genes Immun. 2012;13:437-442.
52. Marcuzzi A, Girardelli M, Bianco AM, et al. Inflammation profile of four early onset Crohn patients. Gene. 2012;493:282-285.
53. Galatola M, Miele E, Strisciuglio C, et al. Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis. World J Gastroenterol. 2013;19:8659-8670.
54. Gasche C, Grundtner P, Zwirn P, et al. Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production. J Immunol. 2003;170:5578-5582.
55. Wang AH, Lam WJ, Han DY, et al. The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Hum Immunol. 2011;72:431-435.
56. Wagner J, Skinner NA, Catto-Smith AG, et al. TLR4, IL10RA, and NOD2 mutation in paediatric Crohn's disease patients: an association with Mycobacterium avium subspecies paratuberculosis and TLR4 and IL10-RA expression. Med Microbiol Immunol. 2013;202:267-276.
57. Glubb DM, Gearry RB, Barclay ML, et al. NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World J Gastroenterol. 2011;17:2829-2837.